Trial Profile
An exploratory study to assess the efficacy and safety of NS-304 in patients with chronic thromboembolic pulmonary hypertension (CTEPH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Sep 2020
Price :
$35
*
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Sponsors Actelion Pharmaceuticals; Nippon Shinyaku
- 03 Sep 2020 Primary endpoint (Change from baseline of pulmonary vascular resistance (PVR)) has not been met, as per Results published in the Circulation Journal
- 03 Sep 2020 Results published in the Circulation Journal
- 16 Jun 2015 New trial record